Loading...
XSHE
002030
Market cap1.25bUSD
Oct 09, Last price  
6.03CNY
1D
1.17%
1Q
18.00%
Jan 2017
-49.67%
IPO
458.33%
Name

Daan Gene Co Ltd

Chart & performance

D1W1MN
XSHE:002030 chart
P/E
—
P/S
11.17
EPS
—
Div yield, %
0.25%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
-32.33%
Revenues
758m
-11.18%
172,538,691207,275,582239,204,077319,601,082369,967,649457,560,392582,692,342854,372,3221,086,153,4331,474,339,1011,612,560,4701,542,429,3441,478,663,1271,098,217,1585,341,209,6277,664,262,20112,046,135,0391,180,897,086853,024,339757,661,908
Net income
-744m
L-19.54%
28,741,86435,036,36634,939,43147,356,35656,452,72868,010,52690,165,004143,765,389153,055,524101,237,346106,685,50986,447,802101,582,98492,181,8492,449,090,1573,618,186,5675,412,341,072104,659,630-925,169,858-744,378,901
CFO
319m
+6.38%
30,086,3088,790,31428,969,05054,351,04878,992,10164,537,1633,371,97226,977,09540,377,289000392,378,50992,972,7132,514,511,5293,304,545,7844,154,852,483845,764,161300,332,716319,489,253
Dividend
Jun 14, 20240.015 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Daan Gene Co., Ltd. specializes in the research, development, manufacturing, and commercialization of clinical diagnostic reagents and instruments. The company's extensive product portfolio encompasses advanced solutions such as fluorescence quantitative PCR products, time-resolved series diagnostics, enzyme-linked immunoassay (EIA) kits, various diagnostic instruments, and specialized scientific research services. Beyond product offerings, the company extends its expertise to provide comprehensive medical examination and health management services. These encompass a wide range of offerings, from genetic susceptibility gene testing and tumor marker analysis to crucial cervical cancer screening and general routine physical examinations, alongside other personalized health support. Established in 2001, the company was originally known as Da An Gene Co., Ltd. of Sun Yat-Sen University. It is presently headquartered in Guangzhou, located in the People's Republic of China.

Key people

Dianhan Wei
Chairman of the Board · since 2025
Zhizheng Huang
Finance Director, Deputy General Manager, Director · since 2025
Yang Wang
Chief Marketing Officer, Deputy General Manager · since 2021
Taosheng Huang
Deputy General Manager, Chief Quality Officer · since 2025
Zhikun Liang
Deputy General Manager, Director · since 2025
Weijie Zhang
Chief Financial Officer, Deputy General Manager · since 2015
Jun'an Hong
Assistant to General Manager · since 2025
Lei Shi
Assistant to General Manager · since 2025
Yifan Yuan
Assistant General Manager · since 2025
Ping Zhang
Assistant to General Manager · since 2025
Jun Zeng
Deputy General Manager, Secretary of the Board · since 2025
Bin Zhang
Deputy General Manager, Secretary of the Board, Director · since 2019
Hongwei Chen
Vice Chairman of the Board, General Manager · since 2025
Wanyu Zhu
Director · since 2025
Jianbing Fan
Independent Director
Independent Director · since 2025
Xinchun Pei
Independent Director · since 2025
IPO date
Aug 09, 2004
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
广州市高新技术产业开发区香山路19号
广州市, GD 510000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT